

# Adnan Kastrati

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9260358/adnan-kastrati-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

643  
papers

66,067  
citations

117  
h-index

245  
g-index

704  
ext. papers

78,506  
ext. citations

7.7  
avg, IF

7.15  
L-index

#	Paper	IF	Citations
643	Antiplatelet therapy after percutaneous coronary intervention.. <i>EuroIntervention</i> , <b>2022</b> , 17, e1371-e1396	3.1	5
642	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.. <i>Circulation: Cardiovascular Interventions</i> , <b>2022</b> , CIRCINTERVENTIONS1200094	6	0
641	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention.. <i>Journal of the American Heart Association</i> , <b>2022</b> , e023493	6	0
640	Management of in-stent restenosis. <i>EuroIntervention</i> , <b>2022</b> , 18, e103-e123	3.1	2
639	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021418	6	0
638	Subphenotyping of Patients With Aortic Stenosis by Unsupervised Agglomerative Clustering of Echocardiographic and Hemodynamic Data. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 2127-2140	5	2
637	Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 98, 857-862	2.7	0
636	Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2021</b> , 74, 584-590	0.7	
635	Guided P2Y inhibitor therapy after percutaneous coronary intervention. <i>Lancet, The</i> , <b>2021</b> , 397, 1423-1425	15	4
634	A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy. <i>European Heart Journal</i> , <b>2021</b> , 42, 1773-1785	9.5	5
633	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1121-1129	16.2	5
632	Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020165	6	1
631	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2021</b> , 14, e010565	6	1
630	Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 753-761	16.2	7
629	Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2021</b> , 141, 7-15	3	1
628	Evaluation of a Low-Dose Radiation Protocol During Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , <b>2021</b> , 139, 71-78	3	
627	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , <b>2021</b> , 42, 1289-1367	9.5	920

626	Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTEMI-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , <b>2021</b> , <i>42</i> , 1368-1378	9.5	17
625	Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , <b>2021</b> , <i>42</i> , 1379-1386	9.5	4
624	The Bayesian Approach and the Results of the ISAR-REACT 5 Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , <i>14</i> , 231-232	5	
623	Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , <b>2021</b> , <i>10</i> , e018304	6	4
622	Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , <b>2021</b> ,	1.6	2
621	Letter by Kessler et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials". <i>Circulation</i> , <b>2021</b> , <i>143</i> , e230-e231	16.7	
620	Antithrombotic treatment in primary percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , <b>2021</b> , <i>19</i> , 313-324	2.5	0
619	Evoluci3n de pacientes tratados con armazones coronarios bioabsorbibles liberadores de everolimus tras su disoluci3n completa. <i>Revista Espanola De Cardiologia</i> , <b>2021</b> , <i>74</i> , 584-590	1.5	2
618	Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention. <i>Future Cardiology</i> , <b>2021</b> , <i>17</i> , 539-547	1.3	
617	Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. <i>EuroIntervention</i> , <b>2021</b> , <i>17</i> , e388-e395	3.1	5
616	Clinical burden and implications of coronary interventions for in-stent restenosis. <i>EuroIntervention</i> , <b>2021</b> , <i>17</i> , e355-e357	3.1	2
615	Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes. <i>International Journal of Cardiology</i> , <b>2021</b> , <i>338</i> , 8-13	3.2	0
614	Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> ,	2.7	1
613	Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2020</b> , <i>57</i> , 520 <sup>3</sup> -528		2
612	SARS-CoV-2 Infection in Asymptomatic Patients Hospitalized for Cardiac Emergencies: Implications for Patient Management. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , <i>7</i> , 599299	5.4	1
611	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , <i>76</i> , 2436-2446	15.1	23
610	Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , <i>76</i> , 2569-2571	15.1	13
609	Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , <i>47</i> , 3074-3083	8.8	3

608	Randomized Comparison of Intensified and Standard P2Y-Receptor-Inhibition Before Elective Percutaneous Coronary Intervention: The SASSICAIA Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008649	6	12
607	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 146-158	15.1	18
606	Hospital admissions with acute coronary syndromes during the COVID-19 pandemic in German cardiac care units. <i>Cardiovascular Research</i> , <b>2020</b> , 116, 1800-1801	9.9	4
605	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest - A propensity score-matched analysis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0218634	3.7	2
604	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2664-2678	15.1	32
603	Relation of Hypocholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 1026-1032	3	1
602	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 348-362	7	8
601	Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 96, 1008-1015	2.7	0
600	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , <b>2020</b> , 41, 3533-3545	9.5	37
599	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 2238-2247	5	11
598	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 436-444	8	30
597	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 2266-2274	5	5
596	Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , <b>2020</b> , 142, 2329-2337	16.7	14
595	Reply: Drug-Coated Balloons Versus Drug-Eluting Stents for Coronary In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1392-1393	15.1	
594	Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2020</b> , 57, 732-739	3	1
593	Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent. <i>Cardiovascular Revascularization Medicine</i> , <b>2020</b> , 21, 277-285	1.6	
592	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , <b>2020</b> , 41, 3715-3728	9.5	52
591	Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials. <i>American Heart Journal</i> , <b>2020</b> , 219, 109-116	4.9	3

590	Clinical outcomes of complete versus incomplete revascularization in patients treated with coronary artery bypass grafting: insights from the TiCAB trial. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2020</b> ,	3	2
589	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1524-1534	59.2	327
588	Alanine aminotransferase as a marker of cardiovascular risk at high and low activity levels. <i>Journal of Laboratory and Precision Medicine</i> , <b>2019</b> , 4, 29-29	1.1	7
587	Subintimal Versus Intraplaque Recanalization of Coronary Chronic Total Occlusions: Mid-Term Angiographic and OCT Findings From the ISAR-OCT-CTO Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 1889-1898	5	9
586	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2032-2042	59.2	395
585	U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. <i>Heart and Vessels</i> , <b>2019</b> , 34, 1104-1112	2.1	1
584	Relationship of left ventricular end-diastolic pressure with extent of myocardial ischemia, myocardial salvage and long-term outcome in patients with ST-segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 93, 901-909	2.7	6
583	Genetically modulated educational attainment and coronary disease risk. <i>European Heart Journal</i> , <b>2019</b> , 40, 2413-2420	9.5	20
582	Monocyte-platelet aggregates affect local inflammation in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , <b>2019</b> , 287, 7-12	3.2	8
581	Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 1059-1068	6.1	8
580	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 1512-1518	9.9	9
579	Sex differences in the outcome after percutaneous coronary intervention - A propensity matching analysis. <i>Cardiovascular Revascularization Medicine</i> , <b>2019</b> , 20, 101-107	1.6	12
578	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , <b>2019</b> , 40, 237-269	9.5	851
577	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , <b>2019</b> , 40, 87-165	9.5	2408
576	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2019</b> , 55, 4-90	3	251
575	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , <b>2019</b> , 40, 2070-2085	9.5	35
574	Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 2432-2440	9.5	28
573	Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1539-1545	7	17

572	Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , <b>2019</b> , 496, 55-61	6.2	8
571	Sex and long-term outcomes after implantation of the Absorb bioresorbable vascular scaffold for treatment of coronary artery disease. <i>EuroIntervention</i> , <b>2019</b> , 15, 615-622	3.1	6
570	Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery. <i>EuroIntervention</i> , <b>2019</b> , 15, e1107-e1114	3.1	8
569	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , <b>2019</b> , 14, 1435-1534	3.1	180
568	One-year clinical outcome with a novel self-expanding transcatheter heart valve. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 94, 783-792	2.7	8
567	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. <i>Circulation</i> , <b>2019</b> , 139, 325-333	16.7	52
566	Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. <i>International Journal of Cardiology</i> , <b>2019</b> , 276, 212-217	3.2	6
565	Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 93, 912-920	2.7	13
564	Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 199-205	3	5
563	Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 167-176	9.5	31
562	High-sensitivity cardiac troponin T in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiology</i> , <b>2019</b> , 73, 333-334	3	
561	Incidental findings in multislice computed tomography prior to transcatheter aortic valve implantation: frequency, clinical relevance and outcome. <i>International Journal of Cardiovascular Imaging</i> , <b>2018</b> , 34, 985-992	2.5	8
560	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , <b>2018</b> , 263, 24-28	3.2	6
559	Rebuttal: Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , <b>2018</b> , 92, 107-108	2.7	
558	Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 788-798	6.1	9
557	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 68-76	5	18
556	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 53-65	5	13
555	Incidencia y predictores de la reestenosis recurrente tras angioplastia con balón farmacológico en reestenosis de stents farmacológicos: proyecto cooperativo ICARUS. <i>Revista Española De Cardiología</i> , <b>2018</b> , 71, 620-627	1.5	8

554	Actualizaci3n ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboraci3n con la EACTS. <i>Revista Espanola De Cardiologia</i> , <b>2018</b> , 71, 42.e1-42.e58	1.5	2
553	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , <b>2018</b> , 39, e1-e33	9.5	18
552	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2018</b> , 71, 42	0.7	16
551	Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2018</b> , 19, 1294-1301	4.1	7
550	Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1973-1982	15.1	32
549	High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiology</i> , <b>2018</b> , 72, 220-226	3	9
548	Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. <i>International Journal of Cardiology</i> , <b>2018</b> , 258, 42-49	3.2	9
547	Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , <b>2018</b> , 91, 215-223	2.7	5
546	Endovascular Treatment for Steno-Occlusive Iliac Artery Disease: Safety and Long-Term Outcome. <i>Angiology</i> , <b>2018</b> , 69, 308-315	2.1	4
545	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2018</b> , 39, 119-177	9.5	4237
544	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , <b>2018</b> , 39, 213-260	9.5	1475
543	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. <i>European Heart Journal</i> , <b>2018</b> , 39, 1591-1601	9.5	31
542	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2018</b> , 53, 34-78	3	149
541	Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2018</b> , 71, 620-627	0.7	4
540	Percutaneous coronary intervention: balloons, stents and scaffolds. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 55-63	6.1	7
539	Neoatherosclerosis in Patients With Coronary Stent Thrombosis: Findings From Optical Coherence Tomography Imaging (A Report of the PRESTIGE Consortium). <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1340-1350	5	25
538	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , <b>2018</b> , 50, 1225-1233	36.3	277
537	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. <i>EuroIntervention</i> , <b>2018</b> , 13, 1565-1573	3.1	29

536	Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. <i>EuroIntervention</i> , <b>2018</b> , 14, 224-231	3.1	13
535	Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience. <i>Vasa - European Journal of Vascular Medicine</i> , <b>2018</b> , 47, 507-512	1.9	2
534	Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 461-468	3	7
533	Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. <i>Clinica Chimica Acta</i> , <b>2018</b> , 476, 130-138	6.2	58
532	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , <b>2018</b> , 19, 480-486	1.6	3
531	Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation: A two-center experience of incidence, outcome and temporal trends from 2010 to 2015. <i>Catheterization and Cardiovascular Interventions</i> , <b>2018</b> , 92, 149-156	2.7	15
530	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e006752	6	15
529	Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e006074	6	9
528	High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e007415	6	82
527	Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials: response to letter by Zaman et al. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 1189-1191	6.1	
526	Implantation of a MitraClip between two previously implanted MitraClips to treat recurrent severe mitral regurgitation. <i>Journal of Cardiology Cases</i> , <b>2017</b> , 15, 50-52	0.6	1
525	Long-Term Outcomes After MitraClip Implantation According to the Presence or Absence of EVEREST Inclusion Criteria. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1255-1261	3	35
524	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 477-485	5	9
523	Reperfusion injury in ST-segment elevation myocardial infarction: the final frontier. <i>Coronary Artery Disease</i> , <b>2017</b> , 28, 253-262	1.4	12
522	Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH). <i>Circulation</i> , <b>2017</b> , 135, 2218-2226	16.7	31
521	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2011-2022	15.1	77
520	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	37
519	Functional Characterization of the Coronary Artery Disease Risk Locus. <i>Circulation</i> , <b>2017</b> , 136, 476-489	16.7	61



518	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2017</b> , 52, 206-217	3	23
517	Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , <b>2017</b> , 244, 93-99 <sup>3,2</sup>		24
516	Prognostic value of alkaline phosphatase in patients with acute coronary syndromes. <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 828-834	3.5	9
515	Alkaline phosphatase and prognosis in patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , <b>2017</b> , 47, 378-387	4.6	27
514	Predictors for long-term survival after transcatheter edge-to-edge mitral valve repair. <i>Journal of Interventional Cardiology</i> , <b>2017</b> , 30, 226-233	1.8	31
513	A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis. <i>American Heart Journal</i> , <b>2017</b> , 188, 53-64	4.9	10
512	Gamma-glutamyl transferase and atrial fibrillation in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , <b>2017</b> , 465, 17-21	6.2	8
511	Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort. <i>Structural Heart</i> , <b>2017</b> , 1, 169-178	0.6	10
510	Multicenter Comparison of Novel Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 2078-2087	5	55
509	Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1079-1088	16.2	63
508	Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). <i>Circulation</i> , <b>2017</b> , 136, 1007-1021	16.7	136
507	Association analyses based on false discovery rate implicate new loci for coronary artery disease. <i>Nature Genetics</i> , <b>2017</b> , 49, 1385-1391	36.3	361
506	Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. <i>Lancet, The</i> , <b>2017</b> , 390, 737-746	40	95
505	Response to the letter to the editor: Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention. <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 1328-1329	3.5	
504	Coronary balloon angioplasty, stents, and scaffolds. <i>Lancet, The</i> , <b>2017</b> , 390, 781-792	40	109
503	Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients. <i>European Heart Journal</i> , <b>2017</b> , 38, 3160-3172	9.5	51
502	Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , <b>2017</b> , 70, 1082.e1-1082.e61	1.5	35
501	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 855-862	16.2	18

500	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 1332-1340	5	57
499	Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 1-10	2.7	4
498	Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 367-374	2.7	6
497	A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis. <i>Heart and Vessels</i> , <b>2017</b> , 32, 376-384	2.1	9
496	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 2548-2556	5	4
495	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1989-1999	7	15
494	State of the art: coronary artery stents - past, present and future. <i>EuroIntervention</i> , <b>2017</b> , 13, 706-716	3.1	41
493	Investigator-driven randomized trials <b>2017</b> , 272-282		
492	Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1731-42	5	54
491	Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents. <i>Circulation: Cardiovascular Interventions</i> , <b>2016</b> , 9,	6	2
490	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2259-2268	15.1	56
489	Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience. <i>Wiener Klinische Wochenschrift</i> , <b>2016</b> , 128, 906-915	2.3	1
488	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1890-901	5	23
487	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. <i>Scientific Reports</i> , <b>2016</b> , 6, 33054	4.9	7
486	Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. <i>Platelets</i> , <b>2016</b> , 27, 796-804	3.6	9
485	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 28-38	5	24
484	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. <i>European Heart Journal</i> , <b>2016</b> , 37, 1538-49	9.5	99
483	Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , <b>2016</b> , 452, 155-60	6.2	15

482	Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , <b>2016</b> , 387, 537-544	40	266
481	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 532-538	3	14
480	Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 784-792	5	42
479	Relation of Gamma-Glutamyl Transferase to Cardiovascular Events in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1427-32	3	11
478	Predictors of Permanent Pacemaker Implantations and New-Onset Conduction Abnormalities With the SAPIEN 3 Balloon-Expandable Transcatheter Heart Valve. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 244-254	5	116
477	Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. <i>Aids</i> , <b>2016</b> , 30, 1413-21	3.5	10
476	Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). <i>Thrombosis Research</i> , <b>2016</b> , 137, 72-78	8.2	5
475	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. <i>Circulation: Cardiovascular Interventions</i> , <b>2016</b> , 9, e002995	6	9
474	Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?. <i>European Heart Journal</i> , <b>2016</b> , 37, 1284-95	9.5	38
473	Gamma-glutamyl transferase and cardiovascular disease. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, 481	3.2	58
472	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. <i>EuroIntervention</i> , <b>2016</b> , 11, 1372-9	3.1	52
471	High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. <i>Vasa - European Journal of Vascular Medicine</i> , <b>2016</b> , 45, 155-61	1.9	9
470	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. <i>EuroIntervention</i> , <b>2016</b> , 11, e1275-82	3.1	
469	Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E417-23	2.6	6
468	Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E1413-E1415	2.6	0
467	Prospective Evaluation of 18F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome. <i>Circulation: Cardiovascular Imaging</i> , <b>2016</b> , 9, e004316	3.9	84
466	A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial. <i>American Heart Journal</i> , <b>2016</b> , 179, 69-76	4.9	12
465	Fluoroscopic calcification-guided optimal deployment projection during transcatheter aortic valve replacement--"The eye of the pigtail." (Follow the right cusp rule--Part II). <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 87, 996-8	2.7	4

464	Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. <i>American Heart Journal</i> , <b>2016</b> , 177, 9-16	4.9	13
463	Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 1127-1132	3.5	7
462	Prognostic Value of High-sensitivity Troponin T After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2016</b> , 69, 746-53	0.7	0
461	Valor pronóstico de la troponina T de alta sensibilidad tras intervención coronaria percutánea en pacientes con enfermedad coronaria estable. <i>Revista Espanola De Cardiologia</i> , <b>2016</b> , 69, 746-753	1.5	12
460	Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients. <i>Coronary Artery Disease</i> , <b>2016</b> , 27, 385-90	1.4	1
459	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 674-84	5	35
458	Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1134-44	59.2	325
457	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 575-84	6.1	15
456	Drug-Coated Balloons for Revascularization of Infrapopliteal Arteries: A Meta-Analysis of Randomized Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1072-80	5	24
455	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 124	8.7	12
454	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , <b>2016</b> , 182, 125-134	4.9	84
453	Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. <i>European Heart Journal</i> , <b>2015</b> , 36, 94-9	9.5	57
452	Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects. <i>BMC Medical Informatics and Decision Making</i> , <b>2015</b> , 15, 9	3.6	2
451	Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. <i>European Heart Journal</i> , <b>2015</b> , 36, 3202-10	9.5	59
450	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 877-84	5	62
449	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Journal of Intensive Care Medicine</i> , <b>2015</b> , 30, 211-21	3	26
448	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. <i>European Heart Journal</i> , <b>2015</b> , 36, 2608-20	9.5	145
447	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. <i>Thrombosis Research</i> , <b>2015</b> , 136, 87-93	8.2	20

446	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2015</b> , 36, 1762-71	9.5	218
445	Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 887-901	6.1	19
444	Optimal imaging for guiding TAVR: transesophageal or transthoracic echocardiography, or just fluoroscopy?. <i>JACC: Cardiovascular Imaging</i> , <b>2015</b> , 8, 361-370	8.4	35
443	Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 904-16	15.1	64
442	Duale Plättcheninhibition nach Stentimplantation: kürzer oder länger. <i>CardioVasc</i> , <b>2015</b> , 15, 41-44	0	2
441	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1619-1629	15.1	331
440	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. <i>Cardiovascular Revascularization Medicine</i> , <b>2015</b> , 16, 156-62	1.6	19
439	Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1308-15	12.7	9
438	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grötzig Lecture ESC 2014. <i>European Heart Journal</i> , <b>2015</b> , 36, 3320-31	9.5	309
437	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. <i>Lancet, The</i> , <b>2015</b> , 386, 655-64	4.0	186
436	Acute and Midterm Outcome After MitraClip Therapy in Patients With Severe Mitral Regurgitation and Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 749-56	3	22
435	Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 39, 35-42	5.1	16
434	Duraci3n del tratamiento antiagregante plaquetario combinado doble tras la implantaci3n de stents farmacoactivos: el jurado contin3a reunido. <i>Revista Espanola De Cardiologia</i> , <b>2015</b> , 68, 827-829	1.5	2
433	Endovascular therapy for steno-occlusive subclavian and innominate artery disease. <i>Circulation Journal</i> , <b>2015</b> , 79, 537-43	2.9	16
432	Procedure-related bleeding in elective percutaneous coronary interventions. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 263-73	4.6	2
431	Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. <i>European Heart Journal</i> , <b>2015</b> , 36, 2147-59	9.5	266
430	Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve: A Single-Center Experience. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 1809-16	5.16	46
429	Overexpansion of the SAPIEN 3 Transcatheter Heart Valve: A Feasibility Study. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 2041-2043	5	38

428	Anatomic guided crossing of a stenotic aortic valve under fluoroscopy: "right cusp rule, part III". <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 119-20	5	10
427	Relation of body mass index to bleeding during percutaneous coronary interventions. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 434-40	3	15
426	Predictors of antiplatelet response to prasugrel during maintenance treatment. <i>Platelets</i> , <b>2015</b> , 26, 53-83.6		16
425	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , <b>2015</b> , 36, 1252-63	9.5	296
424	Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124314	3.7	10
423	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. <i>EuroIntervention</i> , <b>2015</b> , 10, 1425-31	3.1	14
422	Tools and Techniques - Clinical: Fluoroscopic balloon sizing of the aortic annulus before transcatheter aortic valve replacement (TAVR) - follow the "right cusp rule". <i>EuroIntervention</i> , <b>2015</b> , 11, 840-2	3.1	9
421	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. <i>EuroIntervention</i> , <b>2015</b> , 11, 196-203	3.1	27
420	Proximal occlusion versus distal filter for cerebral protection during carotid stenting: updated meta-analysis of randomised and observational MRI studies. <i>EuroIntervention</i> , <b>2015</b> , 11, 238-46	3.1	17
419	First use of an expandable sheath and transcaval access for transcatheter Edwards SAPIEN 3 aortic valve implantation. <i>EuroIntervention</i> , <b>2015</b> , 11, 782-4	3.1	9
418	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , <b>2014</b> , 30, 495-504	2.5	28
417	Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2659-73	3.3	73
416	Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 29-36	5	37
415	Current treatment of in-stent restenosis. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2659-73	3.1	330
414	Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. <i>Heart</i> , <b>2014</b> , 100, 153-9	5.1	263
413	Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 270-6	3.3	15
412	Drug-coated balloon therapy in coronary and peripheral artery disease. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 13-23	14.8	133
411	Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99m-sestamibi SPECT. <i>International Journal of Cardiovascular Imaging</i> , <b>2014</b> , 30, 1357-63	2.5	26

410	ORAL immunosuppressive therapy to prevent in-Stent restenosis (RAMSES) cooperation: a patient-level meta-analysis of randomized trials. <i>Atherosclerosis</i> , <b>2014</b> , 237, 410-7	3.1	11
409	Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 863-71	15.1	77
408	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , <b>2014</b> ,	9.5	3467
407	Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , <b>2014</b> , 175, 484-91	3.2	9
406	Pharmacological inhibition of coronary restenosis: systemic and local approaches. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 2155-71	4	20
405	Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. <i>International Journal of Cardiovascular Imaging</i> , <b>2014</b> , 30, 1087-95	2.5	12
404	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. <i>BMJ, The</i> , <b>2014</b> , 348, g3859	5.9	210
403	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , <b>2014</b> , 35, 2285-94	9.5	79
402	Drug-eluting stent trials: too much non-inferiority, too little progress?. <i>Lancet, The</i> , <b>2014</b> , 383, 386-8	4.0	8
401	Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. <i>Thrombosis Research</i> , <b>2014</b> , 134, 558-64	8.2	36
400	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 342-51	7	34
399	Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 1190-7	7	22
398	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 1041-9	7	13
397	In-Stent-Neoatherosklerose nach perkutaner Koronarintervention. <i>CardioVasc</i> , <b>2014</b> , 14, 46-50	0	1
396	Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2014</b> , 15, 216-25	4.1	33
395	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Journal of</i>	3	588
394	Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , <b>2014</b> , 84, 137-46	2.7	35
393	Impact of in-hospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. <i>American Heart Journal</i> , <b>2014</b> , 168, 862-8.e1	4.9	6

392	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. <i>Catheterization and Cardiovascular Interventions</i> , <b>2014</b> , 83, 182-9	2.7	21
391	Bleeding complications in patients undergoing percutaneous coronary interventions: current status and perspective. <i>Coronary Artery Disease</i> , <b>2014</b> , 25, 247-57	1.4	15
390	Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. <i>Coronary Artery Disease</i> , <b>2014</b> , 25, 658-64	1.4	5
389	Correlates of poor outcome among patients with bleeding after coronary interventions. <i>Coronary Artery Disease</i> , <b>2014</b> , 25, 456-62	1.4	4
388	Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1981-7	27.4	121
387	Safety and efficacy of a potential treatment algorithm by using manual compression repair and ultrasound-guided thrombin injection for the management of iatrogenic femoral artery pseudoaneurysm in a large patient cohort. <i>Circulation: Cardiovascular Interventions</i> , <b>2014</b> , 7, 207-15	6	36
386	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. <i>Cardiovascular Revascularization Medicine</i> , <b>2014</b> , 15, 69-75	1.6	10
385	Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. <i>Cardiovascular Revascularization Medicine</i> , <b>2014</b> , 15, 131-6	1.6	9
384	Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. <i>Clinical Research in Cardiology</i> , <b>2014</b> , 103, 49-56	6.1	10
383	A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis. <i>American Journal of Cardiovascular Disease</i> , <b>2014</b> , 4, 87-99	0.9	12
382	Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. <i>Indian Journal of Medical Research</i> , <b>2014</b> , 140, 392-400	2.9	4
381	Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 81, 522-9	2.7	42
380	Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. <i>JACC: Cardiovascular Imaging</i> , <b>2013</b> , 6, 249-62	8.4	179
379	Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2075-82	15.1	61
378	Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 4002-9	3.2	29
377	Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 1284-93	5	76
376	C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , <b>2013</b> , 14, 264-9	1.6	9
375	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. <i>Lancet, The</i> , <b>2013</b> , 381, 461-7	40	277



374	Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , <b>2013</b> , 165, 537-43	4.9	12
373	The assessment of area at risk and myocardial salvage after coronary revascularization in acute myocardial infarction: comparison between CMR and SPECT. <i>JACC: Cardiovascular Imaging</i> , <b>2013</b> , 6, 358-69	8.4	30
372	Fluoroscopy-guided aortic root imaging for TAVR: "follow the right cusp" rule. <i>JACC: Cardiovascular Imaging</i> , <b>2013</b> , 6, 274-5	8.4	45
371	Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 1267-74	5	216
370	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. <i>American Heart Journal</i> , <b>2013</b> , 166, 534-40	4.9	34
369	Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. <i>Thrombosis Research</i> , <b>2013</b> , 131, 198-203	8.2	14
368	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , <b>2013</b> , 382, 1879-88	40	102
367	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 5162-6	3.2	28
366	Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. <i>Cardiovascular Revascularization Medicine</i> , <b>2013</b> , 14, 84-9	1.6	19
365	Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2013</b> , 66, 435-42	0.7	2
364	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , <b>2013</b> , 66, 53.e1-53.e46	1.5	17
363	SORT OUT V: a new episode in the DES wars. <i>Lancet, The</i> , <b>2013</b> , 381, 609-11	40	2
362	Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 804-10	3	33
361	Stents liberadores de rapamicina sin polímero frente a stents liberadores de paclitaxel con polímero: un análisis de datos de pacientes procedentes de ensayos aleatorizados. <i>Revista Espanola De Cardiologia</i> , <b>2013</b> , 66, 435-442	1.5	10
360	Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 2060-6	15.1	185
359	Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene. <i>Annals of Human Genetics</i> , <b>2013</b> , 77, 47-55	2.2	8
358	Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. <i>American Heart Journal</i> , <b>2013</b> , 165, 80-6	4.9	33
357	Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2013</b> , 6, 354-61	6	44

356	Vascular access and closure in coronary angiography and percutaneous intervention. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 27-40	14.8	37
355	Tissue characterization after drug-eluting stent implantation using optical coherence tomography. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2013</b> , 33, 1376-83	9.4	61
354	Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non ST-segment elevation myocardial infarction. <i>Journal of Interventional Cardiology</i> , <b>2013</b> , 26, 623-9	1.8	2
353	Uric acid and prognosis in angiography-proven coronary artery disease. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 256-66	4.6	31
352	Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2013</b> , 82, E769-76	2.7	13
351	A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. <i>Platelets</i> , <b>2013</b> , 24, 15-25	3.6	7
350	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 517-24	7	12
349	Pathway analysis using genome-wide association study data for coronary restenosis--a potential role for the PARVB gene. <i>PLoS ONE</i> , <b>2013</b> , 8, e70676	3.7	7
348	Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. <i>EuroIntervention</i> , <b>2013</b> , 9, 797-802	3.1	43
347	Statin pretreatment and presentation patterns in patients with coronary artery disease. <i>Cardiology Journal</i> , <b>2013</b> , 20, 52-8	1.4	10
346	Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. <i>Platelets</i> , <b>2012</b> , 23, 395-8	3.6	12
345	Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 381-91	6	36
344	Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials. <i>American Heart Journal</i> , <b>2012</b> , 164, 58-65.e1	4.9	20
343	Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. <i>International Journal of Cardiology</i> , <b>2012</b> , 161, 73-82	3.2	25
342	A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel) study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 159-64	15.1	484
341	Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 369-77	15.1	37
340	New anti-platelet agents: the end of resistance?. <i>Thrombosis Research</i> , <b>2012</b> , 130 Suppl 1, S53-5	8.2	6
339	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. <i>European Heart Journal</i> , <b>2012</b> , 33, 3078-87	8.5	102

338	Association of uric acid with mortality in patients with stable coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , <b>2012</b> , 61, 1780-6	12.7	44
337	Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 769-74	7	9
336	Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 461-7	6.1	41
335	Prognostic value of uric acid in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1260-5	3	53
334	No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 82-8, S1-2	6	34
333	Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 582-9	6	106
332	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , <b>2012</b> , 33, 2569-619	9.5	3978
331	Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUTY and ISAR-REACT 4 trials. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 705-12	6	22
330	No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , <b>2012</b> , 10, 429-32	2.5	11
329	Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Circulation</i> , <b>2012</b> , 125, 1424-31	16.7	165
328	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. <i>European Heart Journal</i> , <b>2012</b> , 33, 1214-22	9.5	296
327	In the bivalirudin era, are we still looking for a potent antiplatelet agent?. <i>Current Vascular Pharmacology</i> , <b>2012</b> , 10, 476-8	3.3	0
326	ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. <i>Cardiology Journal</i> , <b>2012</b> , 19, 61-9	1.4	13
325	Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1325-31	15.1	116
324	Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1569-77	15.1	223
323	Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1980-9	59.2	230
322	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. <i>American Heart Journal</i> , <b>2011</b> , 161, 68-75	4.9	84
321	Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. <i>American Heart Journal</i> , <b>2011</b> , 161, 605-10	4.9	28

320	Response from the authors to: The value of elevated high-sensitivity troponin T. <i>American Heart Journal</i> , <b>2011</b> , 161, e35	4.9	
319	Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. <i>American Heart Journal</i> , <b>2011</b> , 162, 518-26.e5	4.9	42
318	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. <i>American Heart Journal</i> , <b>2011</b> , 162, 740-7	4.9	22
317	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. <i>Clinica Chimica Acta</i> , <b>2011</b> , 412, 1350-6	6.2	16
316	Interleukin 18 gene variation and risk of acute myocardial infarction. <i>Cytokine</i> , <b>2011</b> , 56, 786-91	4	14
315	Variations of specific non-candidate genes and risk of myocardial infarction: a replication study. <i>International Journal of Cardiology</i> , <b>2011</b> , 147, 38-41	3.2	11
314	High platelet reactivity and clinical outcome - fact and fiction. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 191-202	7	50
313	Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. <i>Thrombosis Research</i> , <b>2011</b> , 127, 119-21	8.2	13
312	The chromosome 9p21 region and myocardial infarction in a European population. <i>Atherosclerosis</i> , <b>2011</b> , 217, 220-6	3.1	20
311	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. <i>Lancet, The</i> , <b>2011</b> , 378, 1071-8	40	129
310	Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 107-12	7	34
309	Extended evidence for association between the melanoma inhibitory activity 3 gene and myocardial infarction. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 670-5	7	6
308	Ruptured versus stable plaques in human coronary arteries. <i>Coronary Artery Disease</i> , <b>2011</b> , 22, 345-51	1.4	3
307	Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. <i>European Journal of Clinical Investigation</i> , <b>2011</b> , 41, 1054-62	4.6	11
306	Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2011</b> , 107, 871-8	3	44
305	High-sensitivity troponin T level and angiographic severity of coronary artery disease. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 639-43	3	42
304	Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , <b>2011</b> , 32, 32-40	9.5	145
303	Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 327-33	6.1	16

302	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 561-70	6.1	31
301	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 579-85	6.1	3
300	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 691-9	6.1	7
299	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , <b>2011</b> , 77, 494-501	2.7	12
298	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , <b>2011</b> , 78, 161-6	2.7	12
297	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 999-1014	2.5	3
296	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. <i>European Heart Journal</i> , <b>2011</b> , 32, 1605-13	9.5	158
295	Role of platelet function testing in clinical practice: current concepts and future perspectives. <i>Current Drug Targets</i> , <b>2011</b> , 12, 1836-47	3	9
294	A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 4748-57	5.6	13
293	Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 371-7	6	45
292	Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. <i>Circulation</i> , <b>2011</b> , 124, 624-32	16.7	99
291	Prognostic value of coronary computed tomographic angiography in comparison with calcium scoring and clinical risk scores. <i>Circulation: Cardiovascular Imaging</i> , <b>2011</b> , 4, 16-23	3.9	75
290	Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. <i>European Heart Journal</i> , <b>2011</b> , 32, 1121-33	9.5	71
289	Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 505-13; discussion 513	6	14
288	Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 514-21; discussion 521	6	18
287	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. <i>EuroIntervention</i> , <b>2011</b> , 7, 128-35	3.1	6
286	Platelets contribute to postnatal occlusion of the ductus arteriosus. <i>Nature Medicine</i> , <b>2010</b> , 16, 75-82	50.5	127
285	Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 638-43	7	5

284	4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 1170-80	7	21
283	Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2010</b> , 3, 408-13	6	105
282	Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. <i>Circulation: Cardiovascular Interventions</i> , <b>2010</b> , 3, 27-33	6	109
281	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 1821-30	27.4	778
280	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. <i>European Heart Journal</i> , <b>2010</b> , 31, 582-7	9.5	48
279	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2010</b> , 31, 2482-91	9.5	69
278	Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. <i>European Heart Journal</i> , <b>2010</b> , 31, 1205-11	9.5	64
277	A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 558-65	15.1	48
276	5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2383-9	15.1	291
275	Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2710-6	15.1	162
274	2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2536-43	15.1	102
273	Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 317-8	15.1	169
272	Myocardial perfusion grade, myocardial salvage indices and long-term mortality in patients with acute myocardial infarction and full restoration of epicardial blood flow after primary percutaneous coronary intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2010</b> , 63, 770-8	0.7	4
271	Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 151-9	7	114
270	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. <i>American Heart Journal</i> , <b>2010</b> , 160, 355-61	4.9	16
269	Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. <i>American Heart Journal</i> , <b>2010</b> , 160, 506-12	4.9	131
268	Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. <i>Circulation</i> , <b>2010</b> , 121, 512-8	16.7	444
267	Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 1193-200	7	59

266	Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta-analysis. <i>Atherosclerosis</i> , <b>2010</b> , 208, 171-6	3.1	21
265	Grado de perfusión miocárdica, índices de rescate miocárdico y mortalidad a largo plazo en pacientes con infarto agudo de miocardio y restablecimiento completo del flujo sanguíneo epicárdico tras intervención coronaria percutánea primaria. <i>Revista Espanola De Cardiologia</i> , <b>2010</b> , 63, 770-778	1.5	8
264	Pharmacological prevention and management of restenosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1855-72	4	3
263	Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. <i>Blood Coagulation and Fibrinolysis</i> , <b>2010</b> , 21, 46-52	1	26
262	ISAR--a story of trials with impact on practice. <i>Circulation Journal</i> , <b>2010</b> , 74, 1771-8	2.9	6
261	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 626-32	7	23
260	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Heart and Vessels</i> , <b>2010</b> , 25, 27-34	2.1	18
259	Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. <i>Heart and Vessels</i> , <b>2010</b> , 25, 294-8	2.1	6
258	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. <i>Clinical Research in Cardiology</i> , <b>2010</b> , 99, 13-9	6.1	8
257	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , <b>2010</b> , 99, 345-57	6.1	29
256	One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. <i>Clinical Research in Cardiology</i> , <b>2010</b> , 99, 795-802	6.1	20
255	Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 163-7	3	22
254	Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1212-7	3	42
253	Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. <i>Catheterization and Cardiovascular Interventions</i> , <b>2010</b> , 75, 895-902	2.7	9
252	Is diabetes a leveler of efficacy of DES types?. <i>Catheterization and Cardiovascular Interventions</i> , <b>2010</b> , 75, 335-7	2.7	1
251	Drug-Eluting Stent <b>2010</b> , 114-122		
250	A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. <i>EuroIntervention</i> , <b>2010</b> , 5, 976-980	3.1	10
249	Primary Percutaneous Coronary Intervention <b>2010</b> , 65-77		

248	Cangrelor - a champion lost in translation?. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2382-4	59.2	19
247	Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. <i>Circulation</i> , <b>2009</b> , 119, 1933-40	16.7	249
246	Assessment of platelet function in whole blood by multiple electrode aggregometry: transport of samples using a pneumatic tube system. <i>American Journal of Clinical Pathology</i> , <b>2009</b> , 132, 802-3; author reply 803-4	1.9	10
245	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>European Heart Journal</i> , <b>2009</b> , 30, 2714-21	9.5	199
244	Estimated radiation dose associated with cardiac CT angiography. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 500-7	27.4	746
243	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , <b>2009</b> , 30, 2441-9	9.5	180
242	Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 487-8	27.4	40
241	Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 54, 830-9	7.4	23
240	Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. <i>JACC: Cardiovascular Interventions</i> , <b>2009</b> , 2, 1142-8	5	17
239	Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. <i>JACC: Cardiovascular Interventions</i> , <b>2009</b> , 2, 291-9	5	136
238	No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents. <i>JACC: Cardiovascular Interventions</i> , <b>2009</b> , 2, 1149-55	5	23
237	The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. <i>Biomaterials</i> , <b>2009</b> , 30, 632-7	15.6	52
236	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. <i>Clinica Chimica Acta</i> , <b>2009</b> , 409, 46-51	6.2	6
235	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>American Heart Journal</i> , <b>2009</b> , 157, 628-4e2	4.9	79
234	Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 849-56	15.1	543
233	Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 1760-8	15.1	153
232	Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. <i>JACC: Cardiovascular Imaging</i> , <b>2009</b> , 2, 404-11	8.4	203
231	Impact of myocardial salvage assessed by (99m)Tc-sestamibi scintigraphy on cardiac autonomic function in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. <i>JACC: Cardiovascular Imaging</i> , <b>2009</b> , 2, 449-57	8.4	7



230	Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2009</b> , 62, 354-64	0.7	6
229	Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. <i>Drug Safety</i> , <b>2009</b> , 32, 749-70	5.1	54
228	Patterns of presentation and outcomes of patients with acute coronary syndromes. <i>Cardiology</i> , <b>2009</b> , 113, 198-206	1.6	24
227	Risk of combining PPIs with thienopyridines: fact or fiction?. <i>Lancet, The</i> , <b>2009</b> , 374, 952-954	40	34
226	Stents liberadores de fármacos frente a stents convencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados. <i>Revista Espanola De Cardiologia</i> , <b>2009</b> , 62, 354-364	1.5	27
225	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2009</b> , 30, 916-22	9.5	304
224	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2009</b> , 30, 290-6	9.5	44
223	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>European Heart Journal</i> , <b>2009</b> , 30, 923-31	9.5	104
222	Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 340-344	7	20
221	Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007. <i>EuroIntervention</i> , <b>2009</b> , 4, 427-436	3.1	2
220	Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 340-4	7	2
219	Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 714-9	7	69
218	Lack of support for association between common variation in TNFSF4 and myocardial infarction in a German population. <i>Nature Genetics</i> , <b>2008</b> , 40, 1386-7; author reply 1387-8	36.3	14
217	Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. <i>Clinical Endocrinology</i> , <b>2008</b> , 68, 660-5	3.4	71
216	Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1226-31	3	5
215	Tratamiento de la reestenosis de stents liberadores de paclitaxel mediante implantación de stents liberadores de sirolimus. Resultados angiográficos y clínicos. <i>Revista Espanola De Cardiologia</i> , <b>2008</b> , 61, 1134-1139	1.5	7
214	Treatment of Paclitaxel-Eluting Stent Restenosis With Sirolimus-Eluting Stent Implantation: Angiographic and Clinical Outcomes. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2008</b> , 61, 1134-1139	0.7	
213	Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 690-7	15.1	381

212	Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 1429-37	15.1	118
211	Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 512-7	15.1	58
210	A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 894-904	15.1	141
209	A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 1584-8	15.1	701
208	Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. <i>International Journal of Cardiology</i> , <b>2008</b> , 125, 116-7	3.2	9
207	Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. <i>International Journal of Cardiology</i> , <b>2008</b> , 126, 37-44	3.2	94
206	Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. <i>American Heart Journal</i> , <b>2008</b> , 155, 356-60	4.9	44
205	Circulating homocysteine levels in patients with type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2008</b> , 18, 66-73	4.5	33
204	Fibrinogen genes and myocardial infarction: a haplotype analysis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 758-63	9.4	11
203	Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2008</b> , 29, 1504-9	9.5	41
202	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. <i>European Heart Journal</i> , <b>2008</b> , 29, 455-61	9.5	43
201	Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. <i>European Heart Journal</i> , <b>2008</b> , 29, 2868-76	9.5	81
200	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. <i>European Heart Journal</i> , <b>2008</b> , 29, 1975-82	9.5	158
199	Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. <i>Cardiology</i> , <b>2008</b> , 111, 247-53	1.6	10
198	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. <i>BMJ, The</i> , <b>2008</b> , 337, a1331	5.9	209
197	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2008</b> , 29, 2909-45	9.5	1774
196	Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 1120-6	5.6	31
195	Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2008</b> , 5, 188-9		1

194	Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 688-96	59.2	287
193	Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 99, 121-6	7	237
192	Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. <i>JACC: Cardiovascular Interventions</i> , <b>2008</b> , 1, 535-44	5	44
191	Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischARGE gated SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2008</b> , 35, 906-11	8.8	8
190	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. <i>Clinical Research in Cardiology</i> , <b>2008</b> , 97, 160-8	6.1	11
189	Classification of coronary artery bifurcation lesions and treatments: time for a consensus!. <i>Catheterization and Cardiovascular Interventions</i> , <b>2008</b> , 71, 175-83	2.7	210
188	Drug for a while, polymer for life: Is it a good solution?. <i>Catheterization and Cardiovascular Interventions</i> , <b>2008</b> , 71, 340-1	2.7	3
187	EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. <i>Cardiovascular Research</i> , <b>2008</b> , 77, 580-9	9.9	13
186	Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 616-23	15.1	129
185	Improved noninvasive assessment of coronary artery bypass grafts with 64-slice computed tomographic angiography in an unselected patient population. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 946-50	15.1	137
184	Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1265-71	15.1	32
183	Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 149-56	15.1	79
182	A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 1373-80	15.1	253
181	Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. <i>Catheterization and Cardiovascular Interventions</i> , <b>2007</b> , 70, 359-65	2.7	29
180	Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 203-5	3	111
179	Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 575-8	3	14
178	Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. <i>European Heart Journal</i> , <b>2007</b> , 28, 968-73	9.5	33
177	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. <i>European Heart Journal</i> , <b>2007</b> , 28, 2706-13	9.5	273

176	Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. <i>European Heart Journal</i> , <b>2007</b> , 28, 2720-5	9.5	23
175	Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. <i>European Heart Journal</i> , <b>2007</b> , 28, 3034-41	9.5	114
174	Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients with long-term follow-up. <i>European Heart Journal</i> , <b>2007</b> , 28, 443-9	9.5	190
173	A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. <i>European Heart Journal</i> , <b>2007</b> , 28, 1814-9	9.5	181
172	Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. <i>Human Molecular Genetics</i> , <b>2007</b> , 16, 1821-7	5.6	22
171	Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1030-9	59.2	1025
170	Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: looking for the reasons. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 1711-3	27.4	6
169	No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. <i>Genetics in Medicine</i> , <b>2007</b> , 9, 123-9	8.1	26
168	Platelet function in clopidogrel-treated patients with acute coronary syndrome. <i>Blood Coagulation and Fibrinolysis</i> , <b>2007</b> , 18, 335-9	1	32
167	New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective. <i>Country Review Ukraine</i> , <b>2007</b> , 9, A4-A10		1
166	Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. <i>American Heart Journal</i> , <b>2007</b> , 154, 158.e1-7	4.9	19
165	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. <i>American Heart Journal</i> , <b>2007</b> , 154, 3-11	4.9	86
164	Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. <i>American Heart Journal</i> , <b>2007</b> , 154, 688-93	4.9	74
163	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. <i>Lancet, The</i> , <b>2007</b> , 370, 937-48	40	1141
162	Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 97, 1003-12	7	7
161	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 98, 852-7	7	28
160	N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 1151-6	3	23
159	Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents. <i>Catheterization and Cardiovascular Interventions</i> , <b>2006</b> , 68, 690-5	2.7	6

158	Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2006</b> , 26, 1114-9	9.4	60
157	Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. <i>European Heart Journal</i> , <b>2006</b> , 27, 1900-7	9.5	46
156	Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. <i>European Heart Journal</i> , <b>2006</b> , 27, 2524-9	9.5	59
155	Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2006</b> , 3, 476-7		
154	Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1003-10	27.4	333
153	Radiation dose estimates from cardiac multislice computed tomography in daily practice: impact of different scanning protocols on effective dose estimates. <i>Circulation</i> , <b>2006</b> , 113, 1305-10	16.7	593
152	Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1531-8	27.4	561
151	Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. <i>Circulation</i> , <b>2006</b> , 113, 273-9	16.7	154
150	Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. <i>Circulation</i> , <b>2006</b> , 114, 2040-6	16.7	32
149	Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. <i>Circulation</i> , <b>2006</b> , 113, 2293-300	16.7	220
148	Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. <i>European Heart Journal</i> , <b>2006</b> , 27, 260-6	9.5	171
147	Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 708-14	15.1	134
146	Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 262-7	15.1	8
145	Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 312-8	15.1	186
144	Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 1304-9	15.1	69
143	Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. <i>American Heart Journal</i> , <b>2006</b> , 152, 1133-9	4.9	23
142	Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. <i>American Heart Journal</i> , <b>2006</b> , 151, 1248-54	4.9	10
141	A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. <i>Clinica Chimica Acta</i> , <b>2006</b> , 373, 70-6	6.2	8

140	Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 910-1	7	83
139	Impact of P-glycoprotein on clopidogrel absorption. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 486-501	6.1	302
138	Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2005</b> , 25, 748-53	9.4	117
137	Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. <i>European Heart Journal</i> , <b>2005</b> , 26, 1262-8	9.5	103
136	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. <i>European Heart Journal</i> , <b>2005</b> , 26, 1379-84	9.5	41
135	Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. <i>European Heart Journal</i> , <b>2005</b> , 26, 1475-81	9.5	94
134	Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. <i>Circulation</i> , <b>2005</b> , 111, 2617-22	16.7	119
133	Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. <i>Circulation</i> , <b>2005</b> , 112, 2946-50	16.7	531
132	Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. <i>Clinica Chimica Acta</i> , <b>2005</b> , 360, 178-86	6.2	26
131	Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2005</b> , 15, 418-25	4.5	5
130	Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. <i>American Heart Journal</i> , <b>2005</b> , 150, 344-50	4.9	47
129	Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. <i>American Heart Journal</i> , <b>2005</b> , 150, 550-6	4.9	17
128	Drug-eluting stents for diabetes mellitus: a rush to judgment?. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 479-83	15.1	41
127	Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 828-31	15.1	81
126	A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1999-2003	15.1	20
125	P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. <i>Blood Coagulation and Fibrinolysis</i> , <b>2005</b> , 16, 199-204	1	82
124	Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , <b>2005</b> , 16, 511-5	1	7
123	Critical role of bare-metal stent controls in trials of drug-eluting stents: reply. <i>European Heart Journal</i> , <b>2005</b> , 26, 1687-1687	9.5	

122	Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 553-7	3	54
121	Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 1238-40	3	29
120	Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. <i>Catheterization and Cardiovascular Interventions</i> , <b>2005</b> , 65, 374-80	27	51
119	Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 93, 35-9	7	76
118	Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. <i>Cardiovascular Research</i> , <b>2005</b> , 68, 483-92	9.9	45
117	Genotyping of the angiotensin I-converting enzyme gene insertion/deletion polymorphism by the TaqMan method. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1547-9	5.5	12
116	Distal embolic protection in patients with acute myocardial infarction: attractive concept but no evidence of benefit. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 1116-8	27.4	12
115	Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 165-71	27.4	453
114	Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 2865-72	27.4	183
113	No replication of association between estrogen receptor alpha gene polymorphisms and susceptibility to myocardial infarction in a large sample of patients of European descent. <i>Circulation</i> , <b>2005</b> , 112, 2138-42	16.7	40
112	Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 663-70	59.2	414
111	Prevention of restenosis by systemic drug therapy: back to the future?. <i>Circulation</i> , <b>2005</b> , 112, 2759-61	16.7	23
110	Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. <i>Circulation</i> , <b>2005</b> , 112, 2102-7	16.7	57
109	Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 294, 819-25	27.4	233
108	Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. <i>Annals of Internal Medicine</i> , <b>2005</b> , 143, 392-4	8	65
107	Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). <i>Journal of Invasive Cardiology</i> , <b>2005</b> , 17, 199-202	0.7	5
106	A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 93, 789-91	7	2
105	Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. <i>Journal of Nuclear Medicine</i> , <b>2005</b> , 46, 1782-8	8.9	16

104	PLA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 91, 141-5	7	12
103	The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. <i>European Heart Journal</i> , <b>2004</b> , 25, 335-41	9.5	21
102	Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. <i>European Heart Journal</i> , <b>2004</b> , 25, 1635-40	9.5	14
101	A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 232-8	59.2	481
100	Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting. <i>Journal of Lipid Research</i> , <b>2004</b> , 45, 2221-6	6.3	12
99	Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 291, 947-54	27.4	114
98	Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. <i>Circulation</i> , <b>2004</b> , 110, 1916-9	16.7	160
97	Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. <i>Circulation</i> , <b>2004</b> , 110, 790-5	16.7	138
96	Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. <i>Circulation</i> , <b>2004</b> , 110, 3627-35	16.7	243
95	Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. <i>FASEB Journal</i> , <b>2004</b> , 18, 1285-7	0.9	23
94	Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. <i>European Heart Journal</i> , <b>2004</b> , 25, 1898-902	9.5	68
93	Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 1201-6	3	45
92	Myocardial salvage after reduced-dose thrombolysis combined with glycoprotein IIb/IIIa blockade versus thrombolysis alone in patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2004</b> , 17, 191-7	5.1	2
91	Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR-DIRECT trial). <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 61, 190-5	2.7	10
90	Drug-eluting stents for secondary prevention of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 63, 265-6	2.7	1
89	A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 734-41	15.1	43
88	Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 2133-6	15.1	125
87	A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 2073-9	15.1	45



86	Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. <i>American Heart Journal</i> , <b>2004</b> , 147, 457-62	4.9	86
85	Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. <i>American Heart Journal</i> , <b>2004</b> , 147, 317-22	4.9	86
84	A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. <i>American Heart Journal</i> , <b>2004</b> , 148, e3	4.9	36
83	Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 830-6	2.4	6
82	Pharmacokinetics of clopidogrel after administration of a high loading dose. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 92, 311-6	7	195
81	Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. <i>Atherosclerosis</i> , <b>2004</b> , 174, 105-10	3.1	17
80	Tissue factor promoter polymorphism -603 A/G is associated with myocardial infarction. <i>Atherosclerosis</i> , <b>2004</b> , 177, 189-91	3.1	37
79	ABO locus O1 allele and risk of myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , <b>2004</b> , 15, 61-7	1	23
78	Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. <i>Journal of Nuclear Medicine</i> , <b>2004</b> , 45, 725-9	8.9	60
77	Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. <i>American Journal of Kidney Diseases</i> , <b>2004</b> , 44, 627-35	7.4	6
76	Haptoglobin gene subtyping by restriction enzyme analysis. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 1937-40	5.5	16
75	Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. <i>European Heart Journal</i> , <b>2003</b> , 24, 820-7	9.5	24
74	Gender and restenosis after coronary artery stenting. <i>European Heart Journal</i> , <b>2003</b> , 24, 1523-30	9.5	89
73	Impact of acute myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 341-3	3	1
72	Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. <i>Atherosclerosis</i> , <b>2003</b> , 166, 171-6	3.1	3
71	G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. <i>Atherosclerosis</i> , <b>2003</b> , 167, 135-9	3.1	24
70	Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 925-9	15.1	52
69	Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STERO-2) trial. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1283-8	15.1	439

68	Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1957-61	15.1	16
67	4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. <i>American Heart Journal</i> , <b>2003</b> , 146, 855-61	4.9	18
66	Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. <i>American Heart Journal</i> , <b>2003</b> , 146, 882-6	4.9	38
65	Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. <i>American Journal of Medicine</i> , <b>2003</b> , 114, 715-22	2.4	75
64	Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. <i>Cytokine</i> , <b>2003</b> , 24, 161-71	4	46
63	Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. <i>European Heart Journal</i> , <b>2003</b> , 24, 1128-33	9.5	27
62	Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 290, 1593-9	27.4	294
61	Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. <i>Diabetes Care</i> , <b>2003</b> , 26, 2628-31	14.6	111
60	Leucine 7 to proline 7 polymorphism of the preproneuropeptide Y gene is not associated with restenosis after coronary stenting. <i>Journal of Endovascular Therapy</i> , <b>2003</b> , 10, 566-72	2.5	3
59	Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 2229-34	9.4	18
58	Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. <i>Circulation</i> , <b>2003</b> , 108, 1084-8	16.7	110
57	Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial). <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 58-60	3	11
56	Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. <i>Catheterization and Cardiovascular Interventions</i> , <b>2002</b> , 55, 436-41	2.7	35
55	Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. <i>Circulation</i> , <b>2002</b> , 105, 2946-9	16.7	76
54	Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 210-5	27.4	117
53	Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 13-8	2.4	15
52	Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 882-9	15.1	51
51	Statin treatment following coronary artery stenting and one-year survival. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 854-61	15.1	44

50	Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. <i>Lancet, The</i> , <b>2002</b> , 359, 920-5	40	167
49	CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. <i>American Heart Journal</i> , <b>2002</b> , 143, 971-6	4.9	37
48	Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 1377-82	5.5	72
47	Previous cytomegalovirus infection and restenosis after coronary stent placement. <i>Circulation</i> , <b>2001</b> , 104, 1135-9	16.7	17
46	Restenosis in one lesion in patients with multilesion stenting occurs even when the companion lesion is free of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , <b>2001</b> , 53, 287-8	2.7	2
45	A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , <b>2001</b> , 54, 414-9	2.7	8
44	Restenosis after coronary placement of various stent types. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 34-9	3	226
43	Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 397-400	3	13
42	Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re liquid-filled balloon. <i>American Journal of Cardiology</i> , <b>2001</b> , 87, 463-6, A7	3	19
41	Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 1120-4	3	20
40	Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. <i>Circulation</i> , <b>2001</b> , 103, 2816-21	16.7	567
39	Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. <i>Atherosclerosis</i> , <b>2001</b> , 159, 137-44	3.1	160
38	Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 37, 2066-73	15.1	36
37	Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2001</b> , 357, 2085-9	40	108
36	Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. <i>Catheterization and Cardiovascular Interventions</i> , <b>2000</b> , 50, 290-7	2.7	104
35	Long-term outcome after coronary stenting. <i>Current Controlled Trials in Cardiovascular Medicine</i> , <b>2000</b> , 1, 48-54		29
34	Genetic risk factors and restenosis after percutaneous coronary interventions. <i>Herz</i> , <b>2000</b> , 25, 34-46	2.6	31
33	HPA-1 and HPA-3 Polymorphisms of the Platelet Fibrinogen Receptor and Coronary Artery Disease and Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 83, 559-562	7	58

32	Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. <i>Circulation</i> , <b>2000</b> , 101, 11-3	16.7	25
31	A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. <i>Circulation</i> , <b>2000</b> , 102, 2593-8	16.7	151
30	Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 385-91	59.2	349
29	Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. <i>Circulation</i> , <b>2000</b> , 101, 2478-83	16.7	162
28	Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. <i>Circulation</i> , <b>2000</b> , 102, 197-202	16.7	51
27	Primary intracoronary stenting in acute myocardial infarction: Long-term clinical and angiographic follow-up and risk factor analysis. <i>American Heart Journal</i> , <b>2000</b> , 139, 208-216	4.9	23
26	G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. <i>Atherosclerosis</i> , <b>2000</b> , 149, 151-5	3.1	19
25	PLA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 84-9	15.1	50
24	Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 2168-73	15.1	98
23	Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 35, 915-21	15.1	287
22	Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis. <i>American Heart Journal</i> , <b>2000</b> , 139, 208-16	4.9	3
21	Influence of balloon pressure during stent placement in native coronary arteries on early and late angiographic and clinical outcome: A randomized evaluation of high-pressure inflation. <i>Circulation</i> , <b>1999</b> , 100, 918-23	16.7	61
20	PLA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. <i>Circulation</i> , <b>1999</b> , 99, 1005-10	16.7	139
19	Influence of lesion length on restenosis after coronary stent placement. <i>American Journal of Cardiology</i> , <b>1999</b> , 83, 1617-22	3	179
18	Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. <i>American Journal of Cardiology</i> , <b>1999</b> , 84, 987-91	3	20
17	Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , <b>1999</b> , 48, 151-6	2.7	60
16	Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. <i>Circulation</i> , <b>1999</b> , 100, 1285-90	16.7	101
15	Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 1005-12	15.1	19

14	Clinical and angiographic outcome after stent placement for chronic coronary occlusion. <i>American Journal of Cardiology</i> , <b>1998</b> , 82, 803-6, A9	3	14
13	Operator volume and outcome of patients undergoing coronary stent placement. <i>Journal of the American College of Cardiology</i> , <b>1998</b> , 32, 970-6	15.1	57
12	Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. <i>Journal of the American College of Cardiology</i> , <b>1998</b> , 32, 1866-73	15.1	388
11	Vessel size and long-term outcome after coronary stent placement. <i>Circulation</i> , <b>1998</b> , 98, 1875-80	16.7	375
10	Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. <i>Circulation</i> , <b>1998</b> , 98, 2695-701	16.7	435
9	Intracoronary stenting and risk for major adverse cardiac events during the first month. <i>Circulation</i> , <b>1998</b> , 98, 104-11	16.7	140
8	Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. <i>Circulation</i> , <b>1998</b> , 97, 2396-401	16.7	77
7	Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems. <i>Coronary Artery Disease</i> , <b>1997</b> , 8, 83-90	1.4	35
6	Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. <i>Journal of the American College of Cardiology</i> , <b>1997</b> , 29, 28-34	15.1	108
5	Predictive factors of restenosis after coronary stent placement. <i>Journal of the American College of Cardiology</i> , <b>1997</b> , 30, 1428-36	15.1	544
4	Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. <i>Circulation</i> , <b>1997</b> , 96, 3880-7	16.7	39
3	A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 1084-9	59.2	1625
2	720-6 Stenting for Progressive Dissection During PTCA: Clinical, Angiographic and Intravascular Ultrasound Criteria to Define a Low-risk Group not Requiring Subsequent Anticoagulation. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 25, 123A-124A	15.1	6
1	Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment. <i>Journal of the American College of Cardiology</i> , <b>1994</b> , 23, 1053-60	15.1	62